The All Copays Count Coalition (ACCC), of which IDF is a steering committee member, expressed disappointment with the Department of Health and Human Services' (HHS) decision to appeal a recent U.S. District Court decision vacating a Trump-era regulation that allowed commercial market insurers and pharmacy benefit managers to profit from copay assistance provided to patients with rare and chronic diseases.
A letter signed by 86 members of the Coalition previously asked HHS not to appeal the decision and to immediately issue guidance to health insurance companies to discontinue copay accumulators for medications without generic alternatives.
